Aldeyra Therapeutics, Inc.
ALDX
$4.88
$0.010.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.29% | 1.63% | 37.19% | -4.60% | 10.30% |
| Total Depreciation and Amortization | 2.25% | 2.30% | -5.43% | 2.22% | 2.27% |
| Total Amortization of Deferred Charges | -- | -100.00% | -- | -- | -- |
| Total Other Non-Cash Items | 1,396.38% | -109.69% | 123.47% | -69.44% | 90.26% |
| Change in Net Operating Assets | -232.20% | 128.05% | -265.77% | -33.67% | 104.40% |
| Cash from Operations | 17.93% | 31.39% | -3.60% | -50.93% | 39.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,611.82% | -107.60% | 566.17% | -129.72% | 128.86% |
| Cash from Investing | 4,611.82% | -107.60% | 566.17% | -129.72% | 128.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 186.27% | 1,660.30% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 76.99% | -- |
| Cash from Financing | -- | -100.00% | 12,756.41% | 103.95% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 298.69% | -118.11% | 69.27% | -367.16% | 90.75% |